Single Arm Phase Ib/II Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer: Big Ten Cancer Research Consortium BTCRC-GU16-043
Phase of Trial: Phase I/II
Latest Information Update: 03 Feb 2019
At a glance
- Drugs Durvalumab (Primary) ; Guadecitabine (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 10 Feb 2018 Trial design presented at the 2018 Genitourinary Cancers Symposium
- 16 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2019.
- 16 Jan 2018 Status changed from not yet recruiting to recruiting.